Targeted Diagnostics Ceres Nanosciences specializes in Nanotrap technology to enhance sensitivity and accuracy across diagnostic platforms, presenting opportunities to partner with clinical labs, CROs, and diagnostic developers seeking low-abundance biomarker detection and improved assay performance.

Wastewater Surveillance Strong momentum in wastewater-based epidemiology with NIH RADx funding and partnerships (Biobot Analytics, Emory University) creates sales avenues for diagnostics customers requiring scalable sample prep solutions for environmental and public health surveillance programs.

Product Suite Expansion Recent product launches such as Nanotrap Microbiome B Particles and Nanotrap Enhancement Reagent 3 broaden application areas, offering cross-sell opportunities to existing customers and a path to enter new research segments and assay workflows.

Strategic Partnerships Active collaboration with universities and healthcare systems (Emory, underserved community focus) signals a buyer ecosystem that values enabling technologies; target institutions, contract research organizations, and hospital networks for integration of Nanotrap-based workflows.

Growth and Visibility Private financing and a growing revenue base (likely in the 10–25 million range) indicate scale-up potential; engage strategics and investors-facing sales to align product roadmaps with hospital systems, reference lab networks, and national diagnostic programs.